RDI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
RDI is not a good buy right now. Price is trading below key support levels (under S2), pre-market is sharply down (-7.34%), and there is no Intellectia buy signal to justify an impatient entry. With weakening Q3 fundamentals (revenue down and losses widening) and no fresh news catalyst, the risk/reward is unfavorable for buying immediately.
Trend/price action: The stock is weak relative to its key levels. Current price (~1.01) is below S2 (1.054) and S1 (1.077) and also below the pivot (1.116). That places RDI in a breakdown/bearish zone where prior support has flipped into overhead resistance. Momentum: MACD histogram is slightly positive (0.0042) but is “positively contracting,” which typically signals fading upside momentum rather than a fresh bullish impulse. RSI(6) at ~38.7 leans toward the lower side of neutral (soft/weak demand). Moving averages: Converging MAs suggest consolidation, but given price below support, this consolidation is happening in a weak context. Levels to watch: Immediate resistance is the former support zone 1.05–1.08 (S2/S1). Above that, pivot 1.116 and R1 1.154 are key hurdles. Without reclaiming at least ~1.08–1.12, upside attempts are technically fragile.
Intellectia Proprietary Trading Signals
Margins: Gross margin improved to 8.3% (up YoY), indicating some operational improvement even while revenue fell.
Immediate weakness: Pre-market down -7.34% while the stock is already below major support (below S2 1.054), increasing odds of continuation selling.
Fundamentals deteriorating: 2025/Q3 revenue fell -13.18% YoY and net loss widened (net income -$4.157M, down -40.85% YoY), with EPS -0.18 (down -41.94% YoY).
No near-term news support: No news in the past week to explain/offset the weakness.
Positioning risk: Extremely high IV and call-skew in open interest can unwind quickly in small caps, amplifying downside.
Latest quarter: 2025/Q3. Growth trend: Revenue declined to $52.17M (-13.18% YoY), while profitability worsened—net income decreased to -$4.157M (down -40.85% YoY) and EPS fell to -0.18 (down -41.94% YoY). The one bright spot is gross margin rising to 8.3% (+8.64% YoY), but the overall trend still reflects contraction and deeper losses.
No analyst rating or price target change data was provided, so there’s no clear ‘Wall Street’ pro/con skew to lean on. In the absence of coverage/target revisions, the decision leans more heavily on price action (currently weak) and fundamentals (currently deteriorating). Additionally, hedge fund and insider activity is described as Neutral, and there is no recent Congress trading data or notable politician/influential-figure trading reported.
